These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 24145087)

  • 21. Exendin-4 improves hepatocyte injury by decreasing proliferation through blocking NGF/TrkA in diabetic mice.
    Gezginci-Oktayoglu S; Sacan O; Yanardag R; Karatug A; Bolkent S
    Peptides; 2011 Feb; 32(2):223-31. PubMed ID: 21055431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
    Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
    Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of independent and combined metabolic effects of chronic treatment with (pGlu-Gln)-CCK-8 and long-acting GLP-1 and GIP mimetics in high fat-fed mice.
    Irwin N; Hunter K; Montgomery IA; Flatt PR
    Diabetes Obes Metab; 2013 Jul; 15(7):650-9. PubMed ID: 23388064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces hepatic steatosis and endoplasmic reticulum stress by inducing nuclear factor erythroid-derived 2-related factor 2 nuclear translocation.
    Yoo J; Cho IJ; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    Toxicol Appl Pharmacol; 2018 Dec; 360():18-29. PubMed ID: 30253173
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression.
    Ojima A; Ishibashi Y; Matsui T; Maeda S; Nishino Y; Takeuchi M; Fukami K; Yamagishi S
    Am J Pathol; 2013 Jan; 182(1):132-41. PubMed ID: 23159951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide upregulates gene expression of glucagon-like peptide-1 receptor and nerve growth factor in streptozotocin/nicotinamide-induced diabetic mice.
    Gumuslu E; Cine N; Ertan M; Mutlu O; Komsuoglu Celikyurt I; Ulak G
    Fundam Clin Pharmacol; 2018 Apr; 32(2):174-180. PubMed ID: 29091313
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The novel GLP-1-gastrin dual agonist, ZP3022, increases β-cell mass and prevents diabetes in db/db mice.
    Fosgerau K; Jessen L; Lind Tolborg J; Østerlund T; Schæffer Larsen K; Rolsted K; Brorson M; Jelsing J; Skovlund Ryge Neerup T
    Diabetes Obes Metab; 2013 Jan; 15(1):62-71. PubMed ID: 22862961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Beneficial metabolic effects of dietary epigallocatechin gallate alone and in combination with exendin-4 in high fat diabetic mice.
    Pathak NM; Millar PJB; Pathak V; Flatt PR; Gault VA
    Mol Cell Endocrinol; 2018 Jan; 460():200-208. PubMed ID: 28754350
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
    Jin CH; Chae SY; Son S; Kim TH; Um KA; Youn YS; Lee S; Lee KC
    J Control Release; 2009 Feb; 133(3):172-7. PubMed ID: 18977255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of glucagon-like peptide-1(7-36) and exendin-4 on the vascular reactivity in streptozotocin/nicotinamide-induced diabetic rats.
    Ozyazgan S; Kutluata N; Afşar S; Ozdaş SB; Akkan AG
    Pharmacology; 2005 Jun; 74(3):119-26. PubMed ID: 15746570
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.
    Kan M; Guo G; Singh B; Singh V; Zochodne DW
    J Neuropathol Exp Neurol; 2012 Jun; 71(6):494-510. PubMed ID: 22588388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats.
    Liu WJ; Jin HY; Lee KA; Xie SH; Baek HS; Park TS
    Br J Pharmacol; 2011 Nov; 164(5):1410-20. PubMed ID: 21323903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.
    Sahraoui A; Winzell MS; Gorman T; Smith DM; Skrtic S; Hoeyem M; Abadpour S; Johansson L; Korsgren O; Foss A; Scholz H
    PLoS One; 2015; 10(3):e0121204. PubMed ID: 25793295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exendin-4, a glucagon-like peptide-1 analogue, accelerates diabetic wound healing.
    Roan JN; Cheng HN; Young CC; Lee CJ; Yeh ML; Luo CY; Tsai YS; Lam CF
    J Surg Res; 2017 Feb; 208():93-103. PubMed ID: 27993221
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln.
    Hasib A; Ng MT; Khan D; Gault VA; Flatt PR; Irwin N
    Eur J Pharmacol; 2018 Sep; 834():126-135. PubMed ID: 30025814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of exendin-4 on glucose tolerance, insulin secretion, and beta-cell proliferation depend on treatment dose, treatment duration and meal contents.
    Arakawa M; Ebato C; Mita T; Hirose T; Kawamori R; Fujitani Y; Watada H
    Biochem Biophys Res Commun; 2009 Dec; 390(3):809-14. PubMed ID: 19836346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-like peptide-1 and exendin-4 stimulate beta-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age.
    Tourrel C; Bailbé D; Meile MJ; Kergoat M; Portha B
    Diabetes; 2001 Jul; 50(7):1562-70. PubMed ID: 11423477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Impact of anti-diabetic therapy based on glucagon-like peptide-1 receptor agonists on the cardiovascular risk of patients with type 2 diabetes mellitus].
    Camafort-Babkowski M
    Med Clin (Barc); 2013 Aug; 141(4):167-74. PubMed ID: 23332622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice.
    Park CW; Kim HW; Ko SH; Lim JH; Ryu GR; Chung HW; Han SW; Shin SJ; Bang BK; Breyer MD; Chang YS
    J Am Soc Nephrol; 2007 Apr; 18(4):1227-38. PubMed ID: 17360951
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.